Magazine Article | September 1, 2020

The Holy Grail: Bringing A Vaccine To Market … Soon

Source: Life Science Leader

By Suresh Kumar

Despite divisive leadership that has spawned global mistrust and nationalistic fervor, the world has witnessed unparalleled scientific collaborations — intercontinental, cross-institutional, and cross-functional — among companies, universities, laboratories, and manufacturers to bring a vaccine to market. The result: 250 COVID-19 vaccine candidates in development, 19 of them in safety and dosage testing, 13 more in expanded safety trials, and some entering large-scale Phase 3 trials. National governments and multinational companies are invested. Yet odds are slim that a vaccine demonstrating safety and efficacy via scientific rigor — not political coercion — will be available by year-end. Even having one available during 2021 would be a stupendous achievement.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: